双相释放昂丹司琼改善腹泻型肠易激综合征患者的大便稠度与症状:一项随机双盲试验
该随机双盲试验评估每日12 mg双相释放昂丹司琼片RHB-102治疗腹泻型肠易激综合征(IBS-D)的疗效与安全性。纳入符合罗马III标准、每周至少2天布里斯托大便量表≥6分且日均最严重腹痛强度≥3/10的男女患者,按60:40随机分配至RHB-102或安慰剂组治疗8周。结果显示RHB-102组大便稠度应答率显著高于安慰剂组(56.0% vs 35.3%,P=0.036),腹痛应答和复合应答虽数值上占优但未达统计学显著;基线C反应蛋白高于中位数者应答率更高(59.5% vs 23.1%,P=0.009),不良事件总体相似,RHB-102组便秘发生率更高(13.3% vs 3.9%)但停药后迅速缓解。
要点
- RHB-102组大便稠度应答率56.0%,显著高于安慰剂组的35.3%(P=0.036)。
- 基线C反应蛋白高于中位数(2.09 mg/L)者中,RHB-102组应答率59.5% vs 安慰剂组23.1%(P=0.009)。
- RHB-102组便秘发生率13.3% vs 安慰剂组3.9%,停药后迅速缓解。
核心结论
- RHB-102对男女IBS-D患者的治疗有效且安全,基线C反应蛋白似乎可预测应答。
研究设计与样本
- 随机双盲试验,纳入符合罗马III标准、每周至少2天布里斯托大便量表≥6分且日均最严重腹痛强度≥3/10的男女IBS-D患者,按60:40随机分配至每日一次RHB-102 12 mg或安慰剂,治疗8周。
主要发现
- 总体大便稠度应答率RHB-102组56.0% vs 安慰剂组35.3%(P=0.036),男女患者中相似。
- 总体腹痛应答率RHB-102组50.7% vs 安慰剂组39.2%,复合应答率40.0% vs 25.5%,差异均未达统计学显著。
- 基线C反应蛋白高于中位数(2.09 mg/L)的患者中,大便稠度应答率RHB-102组59.5% vs 安慰剂组23.1%(P=0.009)。
- 不良事件总体发生率相似,RHB-102组便秘发生率13.3% vs 安慰剂组3.9%,停药后迅速缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Previous, small studies have suggested that ondansetron has beneficial effects in diarrhea-predominant irritable bowel syndrome (IBS-D). This randomized, double-blind study evaluated the efficacy and safety of daily 12 mg RHB-102, an investigational bimodal release ondansetron tablet, in IBS-D. METHODS: Men and women with IBS-D by the Rome III criteria, Bristol Stool Scale ≥6 on 2 or more days weekly, and average daily worst pain intensity ≥3/10 were randomized 60:40 to RHB-102 or placebo once daily for 8 weeks. The primary end point was overall stool consistency response for at least 4 of 8 weeks. Secondary end points included overall worst abdominal pain and overall composite response, defined as response on both abdominal pain and stool consistency end points. RESULTS: Overall stool consistency response rates were 56.0% and 35.3% (RHB-102 vs placebo, P = 0.036) and similar among male and female patients. Overall pain response (50.7% vs 39.2%) and composite response rates (40.0% vs 25.5%) favored RHB-102, although these differences were not statistically significant. Stool consistency response rates were enhanced in patients with baseline C-reactive protein above the median (2.09 mg/L), 59.5%, vs 23.1% (P = 0.009). Overall rates of adverse events were similar, with a higher rate of constipation in RHB-102 patients (13.3% vs 3.9%) that resolved rapidly on withholding treatment. DISCUSSION: RHB-102 was effective and safe in the treatment of men and women with IBS-D. Baseline C-reactive protein seemed to be predictive of response.
引用
- Plasse TF, Barton G, Davidson E, et al. Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial. Am J Gastroenterol. 2020. PMID: 32639235. doi:10.14309/ajg.0000000000000727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。